Solventum Announces $1 Billion Share Repurchase Program

Rhea-AI Summary

Solventum (NYSE: SOLV) announced a Board-approved $1 billion share repurchase authorization on Nov 20, 2025.

The company expects to begin repurchases in 2026 and had approximately 173.4 million shares outstanding as of Oct 31, 2025. Repurchases may occur in the open market, via Rule 10b5-1 or 10b-18 plans, privately negotiated transactions, or other means.

The program has no time limit, does not obligate Solventum to buy shares, and may be suspended or discontinued; repurchases will depend on market conditions, liquidity, cash flow and applicable securities laws. Management cited strong cash generation and a concurrent acquisition of Acera Medical as context for the authorization.

Positive

• $1.0B authorized share repurchase
• First-ever company share buyback program announced
• Repurchases expected to begin in 2026

Negative

• Program no time limit and not binding on purchases
• Repurchases subject to market conditions, liquidity and cash flow
• May be suspended or discontinued at any time

ST. PAUL, Minn., Nov. 20, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock.

"Our strong financial performance, operating cash generation, and healthy balance sheet give us the flexibility to invest in opportunities that accelerate sustainable growth, pursue targeted tuck-in M&A—such as today's announced acquisition of Acera Medical to expand our advanced wound care portfolio—and return capital to shareholders," said Bryan Hanson, chief executive officer of Solventum. "Leveraging this momentum, we are pleased to announce Solventum's first share repurchase program, an important step in achieving a more balanced capital allocation strategy."

Solventum expects to begin repurchasing shares in 2026 and had approximately 173.4 million shares outstanding as of October 31, 2025.

Pursuant to the authorization, repurchases may be made from time to time in the open market, including through a Rule 10b5-1 or Rule 10b-18 trading plan, privately negotiated transactions, or other means. In addition, any repurchases under the authorization will be subject to prevailing market conditions, liquidity and cash flow considerations, applicable securities laws requirements (including under Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as applicable), and other factors. The share repurchase program has no time limit, does not require the Company to acquire any amount of shares, and may be suspended or discontinued at any time.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, materials and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Forward-Looking Statements
This news release contains forward-looking information about Solventum's business prospects that contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning in connection with any discussion of future operating plans including any future repurchase of shares. Among the factors that could cause actual results to differ materially from those described in our forward-looking statements are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to Solventum's reputation or its brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events, including the divestiture of our Purification and Filtration business and acquisition of Acera Surgical; (5) Solventum's business dealings involving third-party partners in various markets; (6) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers' research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as "PFAS"; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property rights; (21) pension and postretirement obligation liabilities; (22) any failure by 3M Company ("3M") to perform any of its obligations under the various separation agreements entered into in connection with the separation of Solventum from 3M (the "Spin-Off"); (23) any failure to realize the expected benefits of the Spin-Off; (24) a determination by the IRS or other tax authorities that the Spin-Off or certain related transactions should be treated as taxable transactions; (25) financing transactions undertaken in connection with the Spin-Off and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the Spin-Off will exceed Solventum's estimates; (27) the impact of the Spin-Off on Solventum's businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on Solventum's resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties; (28) changes to Solventum's capital allocation strategy and the timing and form of repurchases; and (29) the price and trading in our common stock.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information, future events or otherwise, except as required by applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-announces-1-billion-share-repurchase-program-302621085.html

SOURCE Solventum

FAQ

What did Solventum (SOLV) announce on November 20, 2025?

Solventum announced a Board-approved $1 billion share repurchase authorization and said repurchases are expected to begin in 2026.

How many Solventum (SOLV) shares were outstanding when the buyback was announced?

Solventum reported approximately 173.4 million shares outstanding as of October 31, 2025.

What methods will Solventum (SOLV) use for repurchases under the $1B program?

Repurchases may be made in the open market, through Rule 10b5-1 or Rule 10b-18 plans, privately negotiated transactions, or other means.

Does the $1 billion repurchase program obligate Solventum (SOLV) to buy shares?

No; the program has no requirement to acquire any shares and may be suspended or discontinued at any time.

When will Solventum (SOLV) start repurchasing shares under the program?

The company expects to begin repurchasing shares in 2026, subject to market and liquidity conditions.